Literature DB >> 33841680

Prediction model of objective response after neoadjuvant chemotherapy in patients with locally advanced gastric cancer.

Wei Xu1, Zhiyuan Fan1, Lingquan Wang1, Changyu He1, Zhentian Ni1, Zichen Hua1, Zhenglun Zhu1, Zhongyin Yang1, Yanan Zheng1, Runhua Feng1, Chao Yan1, Chen Li1, Xuexin Yao1, Mingmin Chen1, Min Yan1, Zhenggang Zhu1, Wentao Liu1.   

Abstract

BACKGROUND: Neoadjuvant chemotherapy (NAC) plays an important role in the therapeutic strategy of locally advanced gastric cancer (LAGC). However, the response of LAGC after NAC varies among different patients. The objective response after NAC has proven to be an excellent indicator for benefiting from NAC, yet effective predictors of objective response are still lacking. The present study aimed to identify potential predictors of objective response in LAGC patients treated with NAC.
METHODS: Clinicopathological data from 267 patients with LAGC who received NAC and met the inclusion criteria between July 2009 and December 2018 were retrospectively reviewed. Patients were randomly divided into the training and test sets at a 2:1 ratio. Univariate analysis was used to investigate whether any factors were correlated with objective response in the training set. Multivariate logistic regression analysis was applied to find independent predictors. A risk score model was then constructed based on the independent predictors, and its performance in predicting objective response was validated in the test set.
RESULTS: Univariate analysis found that gender, age, short axis diameter of the largest regional lymph node (LNmax), serum total protein content, CEA detection value, tumor location, tumor differentiation, signet ring cell carcinoma component and Borrmann type were potential predictors for objective response. In multivariate logistic regression analysis, gender, LNmax and signet ring cell carcinoma component were independent predictors for objective response. Based on independent predictors, we developed a prediction model for objective response.
CONCLUSIONS: We found gender, LNmax and signet ring cell carcinoma component were independent predictors for objective response. The prediction model is a good tool to predict the objective response for LAGC patients treated with NAC, which can be applied to guide clinical practice. AJTR
Copyright © 2021.

Entities:  

Keywords:  Local advanced gastric cancer; neoadjuvant chemotherapy; objective response; prediction model; recist; survival time

Year:  2021        PMID: 33841680      PMCID: PMC8014384     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  31 in total

1.  7th edition of the AJCC cancer staging manual: stomach.

Authors:  Kay Washington
Journal:  Ann Surg Oncol       Date:  2010-12       Impact factor: 5.344

2.  Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.

Authors:  Marc Ychou; Valérie Boige; Jean-Pierre Pignon; Thierry Conroy; Olivier Bouché; Gilles Lebreton; Muriel Ducourtieux; Laurent Bedenne; Jean-Michel Fabre; Bernard Saint-Aubert; Jean Genève; Philippe Lasser; Philippe Rougier
Journal:  J Clin Oncol       Date:  2011-03-28       Impact factor: 44.544

3.  Survival for oesophageal, stomach and small intestine cancers in Europe 1999-2007: Results from EUROCARE-5.

Authors:  L A Anderson; A Tavilla; H Brenner; S Luttmann; C Navarro; A T Gavin; B Holleczek; B T Johnston; M B Cook; F Bannon; M Sant
Journal:  Eur J Cancer       Date:  2015-09-26       Impact factor: 9.162

4.  Estimating postoperative survival of gastric cancer patients and factors affecting it in Iran: Based on a TNM-7 Staging System.

Authors:  Hojjat Zeraati; Zohreh Amiri
Journal:  Acta Med Iran       Date:  2016-02

5.  Cancer statistics in China, 2015.

Authors:  Wanqing Chen; Rongshou Zheng; Peter D Baade; Siwei Zhang; Hongmei Zeng; Freddie Bray; Ahmedin Jemal; Xue Qin Yu; Jie He
Journal:  CA Cancer J Clin       Date:  2016-01-25       Impact factor: 508.702

6.  Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.

Authors:  Shinichi Sakuramoto; Mitsuru Sasako; Toshiharu Yamaguchi; Taira Kinoshita; Masashi Fujii; Atsushi Nashimoto; Hiroshi Furukawa; Toshifusa Nakajima; Yasuo Ohashi; Hiroshi Imamura; Masayuki Higashino; Yoshitaka Yamamura; Akira Kurita; Kuniyoshi Arai
Journal:  N Engl J Med       Date:  2007-11-01       Impact factor: 91.245

7.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.

Authors:  David Cunningham; William H Allum; Sally P Stenning; Jeremy N Thompson; Cornelis J H Van de Velde; Marianne Nicolson; J Howard Scarffe; Fiona J Lofts; Stephen J Falk; Timothy J Iveson; David B Smith; Ruth E Langley; Monica Verma; Simon Weeden; Yu Jo Chua
Journal:  N Engl J Med       Date:  2006-07-06       Impact factor: 91.245

Review 8.  Approaches and genetic determinants in predicting response to neoadjuvant chemotherapy in locally advanced gastric cancer.

Authors:  Jichun Zhou; Jianguo Shen; Benjamin J Seifer; Shaojie Jiang; Ji Wang; Hanchu Xiong; Lingmin Xie; Linbo Wang; Xinbing Sui
Journal:  Oncotarget       Date:  2017-05-02

9.  Perioperative chemotherapy more of a benefit for overall survival than adjuvant chemotherapy for operable gastric cancer: an updated Meta-analysis.

Authors:  Ya'nan Yang; Xue Yin; Lei Sheng; Shan Xu; Lingling Dong; Lian Liu
Journal:  Sci Rep       Date:  2015-08-05       Impact factor: 4.379

Review 10.  Interpretation of the development of neoadjuvant therapy for gastric cancer based on the vicissitudes of the NCCN guidelines.

Authors:  Xian-Ze Wang; Zi-Yang Zeng; Xin Ye; Juan Sun; Zi-Mu Zhang; Wei-Ming Kang
Journal:  World J Gastrointest Oncol       Date:  2020-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.